Thrombophilic mechanisms of OCs

International Journal of Fertility and Women's Medicine

Volumn 42, Issue SUPPL. 1, 1997, Pages 170-176

  Comp, Philip C ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Clotting factors; Deep vein thrombosis; Oral contraceptives; Risk

Indexed keywords

ACTIVATED PROTEIN C; ANDROGEN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; FIBRINOPEPTIDE A; ORAL CONTRACEPTIVE AGENT; PROCOAGULANT; PROTEIN C; PROTEIN S; BLOOD CLOTTING FACTOR 5 LEIDEN;

BLOOD CLOTTING; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; MUTATION; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; THROMBOPHILIA; VEIN THROMBOSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; HEMOSTASIS; PREGNANCY; THROMBOCYTE; THROMBOSIS;

BLOOD PLATELETS; CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; HEMOSTASIS; HUMANS; PREGNANCY; THROMBOSIS;

EID: 0031424592     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Vandenbroucke JP, Koster T, Briët E, et al: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453-1457, 1994.
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346:1582-1588, 1995.
3. Jick H, Jick SS, Gurewich V, et al: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589-1593, 1995.
4. Spitzer WO, Lewis MA, Heinemann LAJ, et al: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J 312:83-88, 1996.
5. Mishell DR, Jr, Darney PD, Milgram L, et alJ: Practice guidelines for OC selection. Dialogues in Contraception 4(7):1-20, 1996.
6. Meade TW, Greenberg G, Thompson SG: Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations. Br Med J 280:1157-1161, 1980.
7. Samisioe G: Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 170:1523-1527, 1994.
8. Daume E: Influence of modern low-dose oral contraceptives on hemostasis. Adv Contracept 6(Suppl): 51-68, 1990.
9. Alving BM, Comp PC: Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 167: 1184-1191, 1992.
10. Speroff L, DeCherney A, and The Advisory Board for the New Progestins: Evaluation of a new generation of oral contraceptives. Obstet Gynecol 81:1034-1047, 1993.
11. Meade TW, Brozovic M, Chakrabarti RR, et al: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet ii:533-537, 1986.
12. Kannel WB, D'Agostino RB, Belanger AJ: Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 113:1006-1010, 1987.
13. Boerger LM, Morris PC, Thurnau GR, et al: Oral contraceptives and gender affect protein S status. Blood 69:692-694, 1987.
14. Malm J, Laurell M, Dahlbäck B: Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 68:437-443, 1988.
15. Engesser L, Broekmans AW, Briet E, Brommer EJP, Bertina RM: Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 106:677-682, 1987.
16. Comp PC, Thurnau GR, Welsh J, et al: Functional and immunologic protein S levels are decreased during pregnancy. Blood 68:881-885, 1986.
17. Broekmans AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 309:340-344, 1983.
18. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004-1008, 1993.
19. Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517-522, 1994.
20. Bertina RM, Koeleman BPC, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.
21. Bertina RM, Reitsma PH, Rosendaal FR, et al: Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 74:449-453, 1995.
22. Dahlbäck B: Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 125:566-571, 1995.
23. Koster T, Rosendaal FR, de Ronde H, et al: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503-1506, 1993.
24. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 90:725-727, 1995.
25. Hellgren M, Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 173:210-213, 1995.
26. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593-1596, 1995.
27. Olivieri O, Friso S, Manzato F, et al: Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 91:465-470, 1995.
28. Henkens CMA, Bom VJJ, Seinen AJ, et al: Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost 73:402-104, 1995.